MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:23 2024-06-24 EDT			Pre-market 02:51:29
67.6 ^EUR	0.00%		67.5	-0.15%

06-24	INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	DP
06-20	Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	DP

MORPHOSYS : Goldman Sachs sticks Neutral

December 12, 2023 at 02:31 am

Rajan Sharma from Goldman Sachs retains his Neutral opinion on the stock. The target price remains set at EUR 17.50.

Latest news about MorphoSys AG

INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	06-23	DP
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Novartis: towards the filing of a buyout offer for MorphoSys	06-20	CF
MorphoSys Set to Delist Following Acquisition by Novartis	06-20	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	06-20	MT
Biotech company Morphosys will soon disappear from the stock exchange	06-20	RE
MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices	06-19	MT
MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	06-09	CI
MorphoSys AG Announces Board Changes	06-06	CI
MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer	06-06	CI
MorphoSys AG Appoints Lukas Gilgen as CFO	06-06	CI
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT
SMA Solar and Morphosys are about to leave the MDax	06-03	RE
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.	05-29	CI
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	05-16	MT
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	05-16	DP
Novartis: presents results of tender offer for MorphoSysy	05-16	CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold	05-16	MT
MORPHOSYS : UBS reiterates its Neutral rating	05-06	ZD
European Equities Traded in the US as American Depositary Receipts Decline	04-30	MT
MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
MORPHOSYS : UBS remains Neutral	04-30	ZD

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.6 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+98.82%	2.73B
MODERNA, INC.	+37.76%	52.5B
IQVIA HOLDINGS INC.	-7.47%	39.01B
LONZA GROUP AG	+37.72%	39.31B
ICON PUBLIC LIMITED COMPANY	+11.93%	26.2B
CELLTRION, INC.	-11.17%	26.57B
ALNYLAM PHARMACEUTICALS, INC.	+16.45%	28.2B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+33.13%	12.62B
BIO-TECHNE CORPORATION	-3.46%	11.74B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : Goldman Sachs sticks Neutral

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research